BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering

路透社2026/10/06 11:26

Show original

On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 6 - ** Spyre Therapeutics (SYRE.O) shares fell 4.1% in premarket trading to $88.90 after the company priced a subsequent $350 million financing

** The biotechnology company announced late Monday (link) that it is offering approximately 4.1 million shares at $85 each, an 8.3% discount to the last closing price

** The company plans to use the net proceeds to advance its projects in gastroenterology, rheumatology, and dermatology, and to move forward with a new project—advancing SPY072 to late-stage development for the chronic skin disease “hidradenitis suppurativa,” among other uses

** Jefferies, TD Cowen, Leerink, and Stifel served as joint bookrunners

** On September 30, Merck (MRK.N)’s drug tulisokibart succeeded in a dermatology clinical trial (link), after which SYRE shares rose roughly 5%; analysts said the data supports SYRE's experimental candidate targeting the same pathway

** SYRE, headquartered in Waltham, Massachusetts, had about 88.2 million shares outstanding before the offering

** As of Monday’s close, the stock has risen 183% year-to-date

** According to LSEG data, out of 17 analysts, 16 give the stock a “strong buy” or “buy” rating, 1 rates it “hold”; the median price target is $123

(To assist non-native English speakers, Reuters automates the translation of its reports into several other languages. Because automated translation may be faulty or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no liability for any damage or loss caused by the use of automated translation functionality.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Updated Pricing Details: On October 6th, before the market opened on Tuesday, shares of the tanker operator Torm (TRMD.O), listed in the US, dropped 3.2% to $39.72 after the company announced the pricing of its secondary offering. According to the company (link), funds managed by Oaktree Capital Management sold approximately 6.3 million shares, raising a total of about $253.5 million. The secondary offering was priced at $40.05 per share, a 2.4% discount to the stock's previous closing price. According to the prospectus, Oaktree Capital completely exited its remaining approximately 6.2% stake following the sale (link). JPMorgan served as the sole underwriter for this issuance. Last month, Oaktree Capital (link) sold shares in another secondary offering of 9 million shares at $32.25 per share. Driven by record freight rates, the shares of tankers listed in Northern Europe (link) have soared, and Torm's stock closed up 2.6% on Monday at $41.05. As of Monday’s close, the company’s US-listed shares had surged about 110% year-to-date, including a 47% gain over the past three months. (For the convenience of non-English speakers, Reuters provides its report with automated translation into several languages. Due to the possibility of errors or the lack of contextual accuracy from automated translation, Reuters does not guarantee the accuracy of these texts. The automated translation is provided for readers’ convenience only. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/06 12:11

BRIEF-Lamb Weston Holdings Announces Quarterly Dividend

Lamb Weston Holdings, Inc. LW.N: LAMB WESTON HOLDINGS ANNOUNCES QUARTERLY DIVIDEND LAMB WESTON HOLDINGS - DECLARES QTRLY DIVIDEND OF $0.38 PER SHARE Source text: ID:nBwWVH9na Further company coverage: LW.N

Reuters•2026/10/06 11:56

XRP Ledger Prints 386% Comeback in Important Metric

UToday•2026/10/06 11:51